Genomics for Life
“Precision Molecular Diagnostics enables the testing of the individual characteristics of each patient and their disease.”
Genomics For Life specializes in advanced technologies to improve patient care including advanced molecular testing of cancers.
For more information on Genomics for Life, please visit their site by clicking here.
Oncofocus® by Oncologica® Ltd. is a comprehensive precision oncology test that precisely identifies the right drug for your cancer thereby increasing your chances of successful treatment.
For more information on Oncofocus, visit their site by clicking here.
PGxOne™ Plus is a pharmacogenomics test that predicts how patients will respond to drug therapy based on their individual genetic makeup. Differences between individuals can affect drug absorption, metabolism, or activity. Therefore, while one treatment regimen may work well for one individual, the same regimen may cause adverse effects for other individuals.1, 2PGxOne™ Plus comprehensively screens 50 well-established pharmacogenomic genes in a single, cost-effective test that provides medically actionable and clinically relevant data, thus allowing physicians to make effective treatment decisions. Expanding beyond pharmacogenomics, PGxOne™ Plus reports potential adverse interactions of the patient’s current medications.
For more information on PGxOne™, visit their site by clicking here.
Precision Oncology is the exclusive distributor for Caris Molecular Intelligence® (CMI) in Australia and New Zealand. We specialise in multiplatform tumour molecular profiling, or in other words, testing a tumour’s unique molecular makeup (DNA, RNA and proteins) to identify which treatments would or would not be most effective in treating that person’s specific cancer.
For more information on Precision Oncology, visit their site by clicking here.
Xing Technologies, next-gen cancer diagnostic pathways for cancer patients. Leaders in point of care detection & monitoring cancer.
For more information on Xing Technologies, visit their site by clicking here.